Is this packet a Phase II decision?
Reuters reported on 27 October 2026 that Swiss start-up Atlast Bio raised $12.5 million, led by Creandum, to run drug trials on virtual patients. This desk does not run those trials. It asks whether a packet is even shaped like a Phase II decision, and it refuses a simulation even when every field is filled.
- Population, endpoint, control, sample-size rationale, estimand, missing-data plan.
- A blank field is not a packet.
- A filled simulation is still a simulation.
Review a packet
Programme licence
USD 100,000 a year, one clinical-development group.
The signer is a head of biostatistics or a VP of clinical development who is being asked to treat a model as the Phase II. The licence is the private gate and four packet reviews. This page does not take a card.